Difference between revisions of "Immunohistochemical staining"

From Libre Pathology
Jump to navigation Jump to search
 
(60 intermediate revisions by 2 users not shown)
Line 1: Line 1:
[[Image:Small_intestine_-_ck20_-_intermed_mag.jpg||thumb|400px|[[CK20]] staining of normal small intestinal mucosa.]]
'''Immunohistochemical staining''', also '''immunostaining''', is a powerful tool.  It is abbreviated '''IHC'''.
'''Immunohistochemical staining''', also '''immunostaining''', is a powerful tool.  It is abbreviated '''IHC'''.


==Utility==
==Utility==
Use of immunohistochemistry:<Ref name=Ref_PCBoD8_175>{{Ref PCPBoD8|175}}</ref>
Use of immunohistochemistry:<Ref name=Ref_PCBoD8_175>{{Ref PCPBoD8|175}}</ref>
#Unknown primary tumours.
#[[Unknown primary tumours]].
#Poorly differentiated tumours.
#Poorly differentiated tumours.
#Prognostic markers, e.g. ERBB2 (HER2).
#Prognostic markers, e.g. ERBB2 (HER2).
#Proving clonality - in the context of hematologic malignancies.
#Proving clonality - in the context of hematologic malignancies.
#Mutation specific antibodies, eg. [[IDH-1]] R132H.
Method was introduced in 1941 by Coons.<ref>{{Cite journal  | last1 = Coons | first1 = AH. | title = The development of immunohistochemistry. | journal = Ann N Y Acad Sci | volume = 177 | issue =  | pages = 5-9 | month = Jun | year = 1971 | doi =  | PMID = 4400556 }}</ref>


==Theory==
==Theory==
*Antigen retrieval.
*Antibody binds to the antigen.
*Antibody binds to the antigen.
*Amplification - needed as the signal is usually too weak.
*Amplification - needed as the signal is usually too weak.


===Antigen retrieval===
===Signaling systems===
*Avidin-biotin complex.
*Avidin-biotin complex.
**Older.<ref>{{Cite journal  | last1 = Vosse | first1 = BA. | last2 = Seelentag | first2 = W. | last3 = Bachmann | first3 = A. | last4 = Bosman | first4 = FT. | last5 = Yan | first5 = P. | title = Background staining of visualization systems in immunohistochemistry: comparison of the Avidin-Biotin Complex system and the EnVision+ system. | journal = Appl Immunohistochem Mol Morphol | volume = 15 | issue = 1 | pages = 103-7 | month = Mar | year = 2007 | doi =  | PMID = 17536316 }}</ref>
**Older.<ref>{{Cite journal  | last1 = Vosse | first1 = BA. | last2 = Seelentag | first2 = W. | last3 = Bachmann | first3 = A. | last4 = Bosman | first4 = FT. | last5 = Yan | first5 = P. | title = Background staining of visualization systems in immunohistochemistry: comparison of the Avidin-Biotin Complex system and the EnVision+ system. | journal = Appl Immunohistochem Mol Morphol | volume = 15 | issue = 1 | pages = 103-7 | month = Mar | year = 2007 | doi =  | PMID = 17536316 }}</ref>
**May suffer from endogenous avidin-biotin activity.<ref name=pmid17536316>{{Cite journal  | last1 = Vosse | first1 = BA. | last2 = Seelentag | first2 = W. | last3 = Bachmann | first3 = A. | last4 = Bosman | first4 = FT. | last5 = Yan | first5 = P. | title = Background staining of visualization systems in immunohistochemistry: comparison of the Avidin-Biotin Complex system and the EnVision+ system. | journal = Appl Immunohistochem Mol Morphol | volume = 15 | issue = 1 | pages = 103-7 | month = Mar | year = 2007 | doi =  | PMID = 17536316 }}</ref>
**May suffer from endogenous avidin-biotin activity.<ref name=pmid17536316>{{Cite journal  | last1 = Vosse | first1 = BA. | last2 = Seelentag | first2 = W. | last3 = Bachmann | first3 = A. | last4 = Bosman | first4 = FT. | last5 = Yan | first5 = P. | title = Background staining of visualization systems in immunohistochemistry: comparison of the Avidin-Biotin Complex system and the EnVision+ system. | journal = Appl Immunohistochem Mol Morphol | volume = 15 | issue = 1 | pages = 103-7 | month = Mar | year = 2007 | doi =  | PMID = 17536316 }}</ref>
***Higher false positive rates than with polymer based methods.
*Polymer based methods.
*Polymer based methods.
**Newer.
**Less prone to false positives.
***Negative controls not needed or infrequently required.<ref name=pmid24714041>{{Cite journal  | last1 = Torlakovic | first1 = EE. | last2 = Francis | first2 = G. | last3 = Garratt | first3 = J. | last4 = Gilks | first4 = B. | last5 = Hyjek | first5 = E. | last6 = Ibrahim | first6 = M. | last7 = Miller | first7 = R. | last8 = Nielsen | first8 = S. | last9 = Petcu | first9 = EB. | title = Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the international ad hoc expert panel. | journal = Appl Immunohistochem Mol Morphol | volume = 22 | issue = 4 | pages = 241-52 | month = Apr | year = 2014 | doi = 10.1097/PAI.0000000000000069 | PMID = 24714041 }}</ref>
===Signal assessment===
*Manual (Morphology) vs. automated (Speed) counting.
*Choice of proper chromogen.
**Dynamic range of DAB is 1-2logs vs. fluorescent probes 2-3logs.
**Protein expression range can be up to 4 logs in gene amplification (information is missed in IHC).
**FastRed stains are more suited in melanocytic tumors than DAB.
*Use of established cutoffs for "intensity" and for "positive" staining.
*Visual pattern recogniton vs. detecting spatial subtle changes.
*Detecting differences at low intensity with human eye is less accurate.


==Quality control==
==Quality control==
This is an evolving area in pathology that has been ignored for a surprisingly long time.   
This is an evolving area in pathology that has been ignored for a surprisingly long time.   


It is touched upon the in the ''[[quality]]'' article in the ''[[Quality#Immunohistochemistry|immunohistochemistry]]'' section.   
It is touched upon the in the ''[[quality]]'' article in the ''[[Quality#Immunohistochemistry|immunohistochemistry]]'' section.
 
There are at least 62 pre-analytical variables to be considered, that may affect staining results.<ref>{{Cite journal | last1 = Engel | first1 = KB. | last2 = Moore | first2 = HM. | title = Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. | journal = Arch Pathol Lab Med | volume = 135 | issue = 5 | pages = 537-43 | month = May | year = 2011 | doi = 10.1043/2010-0702-RAIR.1 | PMID = 21526952 }}</ref>


==Interpretation==
==Interpretation==
Line 31: Line 52:
#*Patchy.
#*Patchy.
#*Diffuse.
#*Diffuse.
#Where it stains the various tissued:
#Where it stains the various tissues:
#*Nucleus.
#*Nucleus.
#*Cytoplasm.
#*Cytoplasm.
Line 37: Line 58:
#*A combination of the above.
#*A combination of the above.


Generally, interpretations are subjective, and this is especially true when the staining is weak and focal. In other words, "... your weak [positive] stain might be somebody else’s negative."<ref>URL: [http://bitesizebio.com/articles/immunohistochemistry-getting-the-stain-you-want/ http://bitesizebio.com/articles/immunohistochemistry-getting-the-stain-you-want/]. Accessed on: 1 September 2012.</ref>
Generally, interpretations can be subjective, and this is especially true when the staining is weak and focal. In other words, "... your weak [positive] stain might be somebody else’s negative."<ref>URL: [http://bitesizebio.com/articles/immunohistochemistry-getting-the-stain-you-want/ http://bitesizebio.com/articles/immunohistochemistry-getting-the-stain-you-want/]. Accessed on: 1 September 2012.</ref>  
 
The cynical might say it is an unwritten rule that: "... if the stain is weak and focal it can be anything you want to make it -- positive or negative -- so it fits perfectly with your diagnosis!"
 
In cases where the morphology is unclear, it is judicious to have two or more immunostains that support the diagnosis, and negative stains for important entities in the differential diagnosis.
 
Publications with contradicting results are not uncommon. Differences can arise from the fixation, processing protocol, antibody clone and interpretation.


The cynical might say it is unwritten rule that: "... if the stain is weak and focal it can be anything you want to make it -- positive or negative -- so it fits perfectly with your diagnosis!"
According to Galloway, one third pathologists substantially overestimate the diagnostic significance of unexpected immunohistochemical staining results.<ref name=pmid21660231>{{Cite journal  | last1 = Galloway | first1 = M. | title = Base-rate error in the interpretation of immunohistochemistry. | journal = Patholog Res Int | volume = 2011 | issue =  | pages = 636495 | month =  | year = 2011 | doi = 10.4061/2011/636495 | PMID = 21660231 }}</ref>


==General (malignant) differential diagnosis==
==General (malignant) differential diagnosis==
Line 52: Line 79:


*Carcinoma.
*Carcinoma.
**AE1/AE3 - pankeratin.
**[[AE1/AE3]] - pankeratin.
**Others: EMA, HMWK, LMWK.
**Others: [[EMA]], HMWK, LMWK.
*Sarcoma.
*Sarcoma.
**Vimentin.
**Vimentin.
***Many pathologists think this stain is totally useless.
***Many pathologists think this stain is totally useless.
*Germ cell tumours.
*Germ cell tumours.
**PLAP (placental-like alkaline phosphatase) - not very sensitive.<ref name=pmid18045648>{{cite journal |author=Iczkowski KA, Butler SL, Shanks JH, ''et al'' |title=Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors |journal=Hum. Pathol. |volume=39 |issue=2 |pages=275-81 |year=2008 |month=February |pmid=18045648 |doi=10.1016/j.humpath.2007.07.002 |url=}}</ref>
**OCT4.
**Others: D2-40, OCT 3/4.
***PLAP ([[placental alkaline phosphatase]]) - not very sensitive.<ref name=pmid18045648>{{cite journal |author=Iczkowski KA, Butler SL, Shanks JH, ''et al'' |title=Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors |journal=Hum. Pathol. |volume=39 |issue=2 |pages=275-81 |year=2008 |month=February |pmid=18045648 |doi=10.1016/j.humpath.2007.07.002 |url=}}</ref>
**[[Glypican 3]] +ve.
*Neuroendocrine carcinoma.
*Neuroendocrine carcinoma.
**Chromogranin A.
**Chromogranin A.
**Synaptophysin.
**Synaptophysin.
**CD56.
**[[CD56]].
**CD57.<ref name=pmid12727026>{{Cite journal  | last1 = Kurokawa | first1 = M. | last2 = Nabeshima | first2 = K. | last3 = Akiyama | first3 = Y. | last4 = Maeda | first4 = S. | last5 = Nishida | first5 = T. | last6 = Nakayama | first6 = F. | last7 = Amano | first7 = M. | last8 = Ogata | first8 = K. | last9 = Setoyama | first9 = M. | title = CD56: a useful marker for diagnosing Merkel cell carcinoma. | journal = J Dermatol Sci | volume = 31 | issue = 3 | pages = 219-24 | month = May | year = 2003 | doi =  | PMID = 12727026 }}</ref>
**CD57.<ref name=pmid12727026>{{Cite journal  | last1 = Kurokawa | first1 = M. | last2 = Nabeshima | first2 = K. | last3 = Akiyama | first3 = Y. | last4 = Maeda | first4 = S. | last5 = Nishida | first5 = T. | last6 = Nakayama | first6 = F. | last7 = Amano | first7 = M. | last8 = Ogata | first8 = K. | last9 = Setoyama | first9 = M. | title = CD56: a useful marker for diagnosing Merkel cell carcinoma. | journal = J Dermatol Sci | volume = 31 | issue = 3 | pages = 219-24 | month = May | year = 2003 | doi =  | PMID = 12727026 }}</ref>
*Melanoma.
*[[Melanoma]].
**S-100, HMB-45, Melan A (MART-1).
**S-100, HMB-45, Melan A (MART-1).
***Additional (UHN): melanoma cocktail (HMB-45, MART-1)<ref name=pmid18360125>{{cite journal |author=Jani P, Chetty R, Ghazarian DM |title=An unusual composite pilomatrix carcinoma with intralesional melanocytes: differential diagnosis, immunohistochemical evaluation, and review of the literature |journal=Am J Dermatopathol |volume=30 |issue=2 |pages=174–7 |year=2008 |month=April |pmid=18360125 |doi=10.1097/DAD.0b013e318165b8fe |url=}}</ref>, microphthalmia,<ref>URL: [http://www.ncbi.nlm.nih.gov/omim/156845 http://www.ncbi.nlm.nih.gov/omim/156845]. Accessed on: 18 August 2010.</ref> tyrosinase.<ref name=pmid17227112>{{Cite journal  | last1 = Roma | first1 = AA. | last2 = Magi-Galluzzi | first2 = C. | last3 = Zhou | first3 = M. | title = Differential expression of melanocytic markers in myoid, lipomatous, and vascular components of renal angiomyolipomas. | journal = Arch Pathol Lab Med | volume = 131 | issue = 1 | pages = 122-5 | month = Jan | year = 2007 | doi = 10.1043/1543-2165(2007)131[122:DEOMMI]2.0.CO;2 | PMID = 17227112 }}</ref>
***Additional: melanoma cocktail (HMB-45, MART-1)<ref name=pmid18360125>{{cite journal |author=Jani P, Chetty R, Ghazarian DM |title=An unusual composite pilomatrix carcinoma with intralesional melanocytes: differential diagnosis, immunohistochemical evaluation, and review of the literature |journal=Am J Dermatopathol |volume=30 |issue=2 |pages=174–7 |year=2008 |month=April |pmid=18360125 |doi=10.1097/DAD.0b013e318165b8fe |url=}}</ref>, microphthalmia,<ref>URL: [http://www.ncbi.nlm.nih.gov/omim/156845 http://www.ncbi.nlm.nih.gov/omim/156845]. Accessed on: 18 August 2010.</ref> tyrosinase.<ref name=pmid17227112>{{Cite journal  | last1 = Roma | first1 = AA. | last2 = Magi-Galluzzi | first2 = C. | last3 = Zhou | first3 = M. | title = Differential expression of melanocytic markers in myoid, lipomatous, and vascular components of renal angiomyolipomas. | journal = Arch Pathol Lab Med | volume = 131 | issue = 1 | pages = 122-5 | month = Jan | year = 2007 | doi = 10.1043/1543-2165(2007)131[122:DEOMMI]2.0.CO;2 | PMID = 17227112 }}</ref>
*Hematologic.
*Hematologic.
**Lymphoma/leukemia.
**Lymphoma/leukemia.
Line 78: Line 106:


==Keratins==
==Keratins==
Classification:<ref>[http://www.nordiqc.org/Epitopes/Cytokeratins/cytokeratins.htm http://www.nordiqc.org/Epitopes/Cytokeratins/cytokeratins.htm]</ref>
{{Main|Keratins}}
*Low molecular weight keratins (LMWK): 7, 8/18, 19, 20.
Mark epithelial cells. Are typically seen in [[carcinoma]]s.
*High molecular weight keratins (HWMK): 4, 10, 13, 14, 17.
 
Uses:
*CK8 (CAM5.2)<ref>{{cite journal |author=Murata T, Nakashima Y, Takeuchi M, Sueishi K, Inomata H |title=The diagnostic use of low molecular weight keratin expression in sebaceous carcinoma |journal=Pathol. Res. Pract. |volume=189 |issue=8 |pages=888–93 |year=1993 |month=September |pmid=7508102 |doi= |url=}}</ref> - used to look for mets from breast cancer in axillary lymph nodes.
*HWMK (e.g. K903<ref>URL: [http://www.aruplab.com/guides/ug/tests/2003978.jsp http://www.aruplab.com/guides/ug/tests/2003978.jsp]. Accessed on: 17 March 2011.</ref>) - [[squamous cell carcinoma]].


==Organ specific==
==Organ specific==
===Thyroid and lung===
===Thyroid and lung===
*TTF-1 ([[thyroid]] transcription factor-1) -- +ve in thyroid gland malignancies.
*TTF-1 ([[thyroid transcription factor-1]]) -- +ve in thyroid gland malignancies.
**Very good for [[breast]] vs. [[lung]].<ref name=pmid18318581>{{cite journal |author=Jagirdar J |title=Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung |journal=Arch. Pathol. Lab. Med. |volume=132 |issue=3 |pages=384–96 |year=2008 |month=March |pmid=18318581 |doi= |url=http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=132&page=384}}</ref>
**Very good for [[breast]] vs. [[lung]].<ref name=pmid18318581>{{cite journal |author=Jagirdar J |title=Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung |journal=Arch. Pathol. Lab. Med. |volume=132 |issue=3 |pages=384–96 |year=2008 |month=March |pmid=18318581 |doi= |url=http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=132&page=384}}</ref>
***Often negative in squamous cell carcinoma of the lung (as with CK7 & CK20), though HMWK is usually positive.
***Often negative in squamous cell carcinoma of the lung (as with [[CK7]] & [[CK20]]), though HMWK is usually positive.
*Thyroglobulin usu. +ve in the thyroid.<ref>{{Cite journal  | last1 = Dralle | first1 = H. | last2 = Böcker | first2 = W. | title = [Thyroglobulin immunohistochemistry: new aspects of pathophysiology and differential diagnosis of benign and malignant goitre (author's transl)]. | journal = Langenbecks Arch Chir | volume = 356 | issue = 3 | pages = 205-12 | month =  | year = 1982 | doi =  | PMID = 7070163 }}</ref>
*Thyroglobulin usu. +ve in the thyroid.<ref>{{Cite journal  | last1 = Dralle | first1 = H. | last2 = Böcker | first2 = W. | title = [Thyroglobulin immunohistochemistry: new aspects of pathophysiology and differential diagnosis of benign and malignant goitre (author's transl)]. | journal = Langenbecks Arch Chir | volume = 356 | issue = 3 | pages = 205-12 | month =  | year = 1982 | doi =  | PMID = 7070163 }}</ref>
**Negative in classic [[medullary thyroid carcinoma]].<ref name=pmid8454270>{{Cite journal  | last1 = de Micco | first1 = C. | last2 = Chapel | first2 = F. | last3 = Dor | first3 = AM. | last4 = Garcia | first4 = S. | last5 = Ruf | first5 = J. | last6 = Carayon | first6 = P. | last7 = Henry | first7 = JF. | last8 = Lebreuil | first8 = G. | title = Thyroglobulin in medullary thyroid carcinoma: immunohistochemical study with polyclonal and monoclonal antibodies. | journal = Hum Pathol | volume = 24 | issue = 3 | pages = 256-62 | month = Mar | year = 1993 | doi =  | PMID = 8454270 }}</ref>
**Negative in classic [[medullary thyroid carcinoma]].<ref name=pmid8454270>{{Cite journal  | last1 = de Micco | first1 = C. | last2 = Chapel | first2 = F. | last3 = Dor | first3 = AM. | last4 = Garcia | first4 = S. | last5 = Ruf | first5 = J. | last6 = Carayon | first6 = P. | last7 = Henry | first7 = JF. | last8 = Lebreuil | first8 = G. | title = Thyroglobulin in medullary thyroid carcinoma: immunohistochemical study with polyclonal and monoclonal antibodies. | journal = Hum Pathol | volume = 24 | issue = 3 | pages = 256-62 | month = Mar | year = 1993 | doi =  | PMID = 8454270 }}</ref>
Line 97: Line 120:


===Breast markers===
===Breast markers===
*GCDFP-15 ([[AKA]] BRST-2) -- specific, but NOT sensitive.
*[[GCDFP-15]] ([[AKA]] BRST-2) -- specific, but NOT sensitive.
*ER (estrogen receptor) - in normal [[breast]].
*[[Estrogen receptor|ER]] (estrogen receptor) - in normal [[breast]].
*PR (progesterone receptor) - in normal breast.
*PR (progesterone receptor) - in normal breast.
*HER2/neu - pathological, assoc. with worse prognosis.
*HER2/neu - pathological, assoc. with worse prognosis.
Line 104: Line 127:


===Prostate gland===
===Prostate gland===
*PSA - [[prostate gland|prostatic]]-specific antigen.
*[[PSA]] - [[prostate gland|prostatic]]-specific antigen.
*PSAP - prostatic-specific acid phosphatase.
*[[PSAP]] - prostatic-specific acid phosphatase.
**May be positive in hindgut [[neuroendocrine tumour]]s.<ref name=pmid>{{Cite journal  | last1 = Azumi | first1 = N. | last2 = Traweek | first2 = ST. | last3 = Battifora | first3 = H. | title = Prostatic acid phosphatase in carcinoid tumors. Immunohistochemical and immunoblot studies. | journal = Am J Surg Pathol | volume = 15 | issue = 8 | pages = 785-90 | month = Aug | year = 1991 | doi =  | PMID = 1712549 }}</ref>
**May be positive in hindgut [[neuroendocrine tumour]]s.<ref name=pmid1712549>{{Cite journal  | last1 = Azumi | first1 = N. | last2 = Traweek | first2 = ST. | last3 = Battifora | first3 = H. | title = Prostatic acid phosphatase in carcinoid tumors. Immunohistochemical and immunoblot studies. | journal = Am J Surg Pathol | volume = 15 | issue = 8 | pages = 785-90 | month = Aug | year = 1991 | doi =  | PMID = 1712549 }}</ref>
*p63 - stains nuclei of basal cell in normal [[prostate]].
*[[p63]] - stains nuclei of basal cell in normal [[prostate]].
*34betaE12 - stains basal cells in normal prostate.
*34betaE12 - stains basal cells in normal prostate.
*AMACR (racemase, P504S<ref>[http://www.antibodies-online.com/antibody/125649/P504S+alphaMethylacylCoA+Racemace+AMACR+Human/ http://www.antibodies-online.com/antibody/125649/P504S+alphaMethylacylCoA+Racemace+AMACR+Human/]</ref>) - present in adenocarcinoma (NOT in normal prostate).
*AMACR (racemase, P504S<ref>[http://www.antibodies-online.com/antibody/125649/P504S+alphaMethylacylCoA+Racemace+AMACR+Human/ http://www.antibodies-online.com/antibody/125649/P504S+alphaMethylacylCoA+Racemace+AMACR+Human/]</ref>) - present in adenocarcinoma (NOT in normal prostate).
*AR - usually present in prostate confined cancers.<ref name=pmid20878946>{{Cite journal  | last1 = Fleischmann | first1 = A. | last2 = Rocha | first2 = C. | last3 = Schobinger | first3 = S. | last4 = Seiler | first4 = R. | last5 = Wiese | first5 = B. | last6 = Thalmann | first6 = GN. | title = Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases. | journal = Prostate | volume = 71 | issue = 5 | pages = 453-60 | month = Apr | year = 2011 | doi = 10.1002/pros.21259 | PMID = 20878946 }}</ref>
*[[Androgen receptor|AR]] - usually present in prostate confined cancers.<ref name=pmid20878946>{{Cite journal  | last1 = Fleischmann | first1 = A. | last2 = Rocha | first2 = C. | last3 = Schobinger | first3 = S. | last4 = Seiler | first4 = R. | last5 = Wiese | first5 = B. | last6 = Thalmann | first6 = GN. | title = Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases. | journal = Prostate | volume = 71 | issue = 5 | pages = 453-60 | month = Apr | year = 2011 | doi = 10.1002/pros.21259 | PMID = 20878946 }}</ref>
*CAP cocktail - [[AKA]] ''CAP'', [[AKA]] ''PIN-4'', [[AKA]] ''PIN''.
*CAP cocktail - [[AKA]] ''CAP'', [[AKA]] ''PIN-4'', [[AKA]] ''PIN''.
**Consists of: AMACR, p63 and HMWK.
**Consists of: AMACR, [[p63]] and HMWK.
**Image: [http://www.webpathology.com/image.asp?case=96&n=5 CAP cocktail (webpathology.com)].
**Image: [http://www.webpathology.com/image.asp?case=96&n=5 CAP cocktail (webpathology.com)].


===[[Colorectal tumours|Colorectal carcinoma]] markers===
===[[Colorectal tumours|Colorectal carcinoma]] markers===
*CK20.
*[[CK20]].
*CDX2.
*CDX2.
**Uncommon in primary lung, breast, pancreas, kidney, gallbladder, liver, urinary bladder, thyroid gland.<ref name=pmid15205684 >{{Cite journal  | last1 = Kaimaktchiev | first1 = V. | last2 = Terracciano | first2 = L. | last3 = Tornillo | first3 = L. | last4 = Spichtin | first4 = H. | last5 = Stoios | first5 = D. | last6 = Bundi | first6 = M. | last7 = Korcheva | first7 = V. | last8 = Mirlacher | first8 = M. | last9 = Loda | first9 = M. | title = The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. | journal = Mod Pathol | volume = 17 | issue = 11 | pages = 1392-9 | month = Nov | year = 2004 | doi = 10.1038/modpathol.3800205 | PMID = 15205684 }}</ref>
**Uncommon in primary lung, breast, pancreas, kidney, gallbladder, liver, urinary bladder, thyroid gland.<ref name=pmid15205684 >{{Cite journal  | last1 = Kaimaktchiev | first1 = V. | last2 = Terracciano | first2 = L. | last3 = Tornillo | first3 = L. | last4 = Spichtin | first4 = H. | last5 = Stoios | first5 = D. | last6 = Bundi | first6 = M. | last7 = Korcheva | first7 = V. | last8 = Mirlacher | first8 = M. | last9 = Loda | first9 = M. | title = The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. | journal = Mod Pathol | volume = 17 | issue = 11 | pages = 1392-9 | month = Nov | year = 2004 | doi = 10.1038/modpathol.3800205 | PMID = 15205684 }}</ref>
*CEA.
*[[CEA]].


===[[Small bowel]]===
===[[Small bowel]]===
*CDX2.
*[[CDX2]].
*Villin.
*[[Villin]].


===[[Kidney tumours|Kidney]]===  
===[[Kidney tumours|Kidney]]===  
[[Renal cell carcinoma]]:
[[Renal cell carcinoma]]:
*RCC, EMA, CD10.
*RCC, [[EMA]], CD10.
*CK7 -ve in clear cell RCC.
*[[CK7]] -ve in clear cell RCC.
*[[AMACR]] +ve in papillary RCC.
*[[AMACR]] +ve in papillary RCC.
*D2-40 +ve in ChRCC.
*D2-40 +ve in ChRCC.
Line 136: Line 159:


===[[Ovarian tumours|Ovary]]===
===[[Ovarian tumours|Ovary]]===
*CA125, CK7+, CK20-.
*[[CA125]], [[CK7]]+, CK20-.
*WT1 -- 90% in serous +ve.
*WT1 -- 90% in serous +ve.


====Serous markers====
====Serous markers====
*WT-1, CA-125, D2-40.
*[[WT-1]], [[CA125]], D2-40.


===[[Liver neoplasms|Liver]]===
===[[Liver neoplasms|Liver]]===
Line 146: Line 169:
*Glypican-3.
*Glypican-3.
**[[Hepatocellular carcinoma]] (HCC) stains with glypican 3, while [[liver]] with dysplastic changes and/or [[cirrhosis|cirrhotic changes]] does not.<ref>{{cite journal  | author=Anatelli F, Chuang ST, Yang XJ, Wang HL. |title=Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy |journal=Am J Clin Pathol. |volume=130 |issue= 2 |pages= 219-23? |year= 2008 |pmid= 18628090 |doi= 10.1309/WMB5PX57Y4P8QCTY }}</ref>
**[[Hepatocellular carcinoma]] (HCC) stains with glypican 3, while [[liver]] with dysplastic changes and/or [[cirrhosis|cirrhotic changes]] does not.<ref>{{cite journal  | author=Anatelli F, Chuang ST, Yang XJ, Wang HL. |title=Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy |journal=Am J Clin Pathol. |volume=130 |issue= 2 |pages= 219-23? |year= 2008 |pmid= 18628090 |doi= 10.1309/WMB5PX57Y4P8QCTY }}</ref>
*HepPar-1 (hepatocytes paraffin antibody 1) - labels hepatocellular mitochondria.<ref name=pmid12502967>The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review. Lamps LW, Folpe AL. Adv Anat Pathol. 2003 Jan;10(1):39-43. Review. PMID 12502967.</ref>
*[[HepPar-1]] (hepatocytes paraffin antibody 1) - labels hepatocellular mitochondria.<ref name=pmid12502967>The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review. Lamps LW, Folpe AL. Adv Anat Pathol. 2003 Jan;10(1):39-43. Review. PMID 12502967.</ref>


[[HCC]] vs. [[cholangiocarcinoma]]:
[[HCC]] vs. [[cholangiocarcinoma]]:
Line 155: Line 178:
*Mesothelial markers:
*Mesothelial markers:
**Calretinin.
**Calretinin.
**WT-1.
**[[WT-1]].
**D2-40.
**D2-40.
**CK5/6.
**[[CK5/6]].
*Carcinoma markers:
*Carcinoma markers:
**CEA (monoclonal and polyclonal).
**CEA (monoclonal and polyclonal).
**TTF-1.
**[[TTF-1]].
**Ber-EP4.
**[[Ber-EP4]].
**MOC-31.
**MOC-31.


Line 181: Line 204:
*Synaptophysin.
*Synaptophysin.
*Chromogranin.
*Chromogranin.
Glial/Neuronal:
*[[MAP2]]
*[[CD56]]


Specific entities:
Specific entities:
*EMA +ve: [[meningioma]], [[ependymoma]] (cytoplasm dot-like).<ref name=Ref_PSNP12>{{Ref PSNP|12}}</ref>
*[[EMA]] +ve: [[meningioma]], [[ependymoma]] (cytoplasm dot-like).<ref name=Ref_PSNP12>{{Ref PSNP|12}}</ref>
*[[ATRX]] -ve: [[astrocytoma]].
*[[INI1]] -ve: [[AT/RT]].


Tumour (low-grade gliomas):
Tumour (low-grade gliomas):
*IDH-1 +ve.
*[[IDH-1]] +ve.
**Usually negative in [[glioblastoma]].
**Usually negative in [[glioblastoma]].


Line 213: Line 242:
===Liver versus bile duct===
===Liver versus bile duct===
Intrahepatic cholangiocarcinoma (ICC) vs. hepatocellular carcinoma (HCC):<ref name=pmid19173916>[Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma] Dong H, Cong WL, Zhu ZZ, Wang B, Xian ZH, Yu H. Zhonghua Zhong Liu Za Zhi. 2008 Sep;30(9):702-5. Chinese. PMID 19173916.</ref>
Intrahepatic cholangiocarcinoma (ICC) vs. hepatocellular carcinoma (HCC):<ref name=pmid19173916>[Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma] Dong H, Cong WL, Zhu ZZ, Wang B, Xian ZH, Yu H. Zhonghua Zhong Liu Za Zhi. 2008 Sep;30(9):702-5. Chinese. PMID 19173916.</ref>
*ICC: CK19 (92.5%), MUC-1 (73.8%) +ve.
*ICC: [[CK19]] (92.5%), [[MUC-1]] (73.8%) +ve.
*HCC: HepPar-1 (85.6%), CD34 (87.8%) +ve.
*HCC: HepPar-1 (85.6%), CD34 (87.8%) +ve.


===Prostate versus bladder===
===Prostate versus bladder===
Prostate adenocarcinoma vs. urothelial carcinoma:  
Prostate adenocarcinoma vs. urothelial carcinoma:  
*Prostate adenocarcioma: PSA +ve, PSAP +ve, AR +ve, CK7 -ve, CK20 -ve.
*Prostate adenocarcinoma: PSA +ve, PSAP +ve, AR +ve, CK7 -ve, CK20 -ve, GATA3 -ve.
*Urothelial carcinoma: CK7 +ve, CK20 +ve, PSA -ve, PSAP -ve, AR -ve.
*Urothelial carcinoma: [[GATA3]] +ve, CK7 +ve, CK20 +ve, PSA -ve, PSAP -ve, AR -ve.


===Breast versus ovary===
===Breast versus ovary===
Breast carcinoma versus ovarian carcinoma:
Breast carcinoma versus ovarian carcinoma:
*Ovary: WT-1 +ve, PAX8 +ve.<ref name=pmid18724243>{{Cite journal  | last1 = Nonaka | first1 = D. | last2 = Chiriboga | first2 = L. | last3 = Soslow | first3 = RA. | title = Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. | journal = Am J Surg Pathol | volume = 32 | issue = 10 | pages = 1566-71 | month = Oct | year = 2008 | doi = 10.1097/PAS.0b013e31816d71ad | PMID = 18724243 }}</ref>
*Ovary: [[WT-1]] +ve, [[PAX8]] +ve.<ref name=pmid18724243>{{Cite journal  | last1 = Nonaka | first1 = D. | last2 = Chiriboga | first2 = L. | last3 = Soslow | first3 = RA. | title = Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. | journal = Am J Surg Pathol | volume = 32 | issue = 10 | pages = 1566-71 | month = Oct | year = 2008 | doi = 10.1097/PAS.0b013e31816d71ad | PMID = 18724243 }}</ref>
*Breast: mammaglobin +ve,<ref name=pmid18753974>{{Cite journal  | last1 = Kanner | first1 = WA. | last2 = Galgano | first2 = MT. | last3 = Stoler | first3 = MH. | last4 = Mills | first4 = SE. | last5 = Atkins | first5 = KA. | title = Distinguishing breast carcinoma from Müllerian serous carcinoma with mammaglobin and mesothelin. | journal = Int J Gynecol Pathol | volume = 27 | issue = 4 | pages = 491-5 | month = Oct | year = 2008 | doi = 10.1097/PGP.0b013e31817d5340 | PMID = 18753974 }}</ref> BRST2 +ve.
*Breast: mammaglobin +ve,<ref name=pmid18753974>{{Cite journal  | last1 = Kanner | first1 = WA. | last2 = Galgano | first2 = MT. | last3 = Stoler | first3 = MH. | last4 = Mills | first4 = SE. | last5 = Atkins | first5 = KA. | title = Distinguishing breast carcinoma from Müllerian serous carcinoma with mammaglobin and mesothelin. | journal = Int J Gynecol Pathol | volume = 27 | issue = 4 | pages = 491-5 | month = Oct | year = 2008 | doi = 10.1097/PGP.0b013e31817d5340 | PMID = 18753974 }}</ref> BRST2 +ve.


Line 250: Line 279:


====CLL====
====CLL====
*CD5 +ve, CD23 +ve.
*CD5 +ve, [[CD23]] +ve.


====[[Mantle cell lymphoma]]====
====[[Mantle cell lymphoma]]====
Line 267: Line 296:
===[[Seminoma]]===
===[[Seminoma]]===
*D2-40 +ve.<ref name=pmid18045648/>
*D2-40 +ve.<ref name=pmid18045648/>
*OCT 3/4 +ve.
*OCT4 +ve.


===[[Embryonal carcinoma]]===
===[[Embryonal carcinoma]]===
Line 301: Line 330:
*S-100 - neural differentiation, melanoma.
*S-100 - neural differentiation, melanoma.
*Desmin - smooth muscle.
*Desmin - smooth muscle.
*MIB1 - proliferation marker (target is Ki-67 protein).
*[[MIB1]] - proliferation marker (target is [[Ki-67]] protein).
*CD99 - blue small cell tumours, membranous staining [[EWS]].
*CD99 - blue small cell tumours, membranous staining [[EWS]].
*BCL2 - [[synovial sarcoma]], [[small cell lymphomas]], spindle cell lipoma.<ref name=Ref_DCHH107>{{Ref DCHH|107}}</ref><ref>URL: [http://ajp.amjpathol.org/cgi/content/full/160/3/759 http://ajp.amjpathol.org/cgi/content/full/160/3/759]. Accessed on: 3 August 2010.</ref>
*BCL2 - [[synovial sarcoma]], [[small cell lymphomas]], spindle cell lipoma.<ref name=Ref_DCHH107>{{Ref DCHH|107}}</ref><ref>URL: [http://ajp.amjpathol.org/cgi/content/full/160/3/759 http://ajp.amjpathol.org/cgi/content/full/160/3/759]. Accessed on: 3 August 2010.</ref>
Line 308: Line 337:
*Caldesmon - muscle.
*Caldesmon - muscle.
*PDGFR - GIST.
*PDGFR - GIST.
*[[STAT6]] - [[Hemangiopericytoma]]/SFT.


==Muscle markers==
==Muscle markers==
Line 361: Line 391:
Mnemonic: ''NASH TURP''.
Mnemonic: ''NASH TURP''.


==Vimentin & cytokeratin==
==Vimentin and cytokeratin positivity==
{{Main|Vimentin#Vimentin_and_cytokeratin_positivity}}
A few tumours are positive for both vimentin and cytokeratins.
A few tumours are positive for both vimentin and cytokeratins.


Common tumours:
==Sarcomas and cytokeratins==
*[[Renal cell carcinoma]].
{{Main|Keratins}}
*[[Endometrial carcinoma]].<ref name=pmid12647218/>
 
Common tumours that uncommonly have the pattern:
*[[Gastric adenocarcinoma]].<ref>URL: [http://cat.inist.fr/?aModele=afficheN&cpsidt=2504165 http://cat.inist.fr/?aModele=afficheN&cpsidt=2504165]. Accessed on: 26 April 2011.</ref>
 
Rare tumours:
*[[Synovial sarcoma]].<ref name=pmid15338724>{{cite journal |author=Llombart-Bosch A, Lopez-Guerrero JA, Peydro-Olaya A |title=Synovial sarcoma (SS): new perspectives supported by modern technology |journal=Arkh. Patol. |volume=64 |issue=3 |pages=39–47 |year=2002 |pmid=15338724 |doi= |url=}}</ref>
*[[Rhabdoid tumour]].<ref name=pmid11557780>{{cite journal |author=Itakura E, Tamiya S, Morita K, ''et al.'' |title=Subcellular distribution of cytokeratin and vimentin in malignant rhabdoid tumor: three-dimensional imaging with confocal laser scanning microscopy and double immunofluorescence |journal=Mod. Pathol. |volume=14 |issue=9 |pages=854–61 |year=2001 |month=September |pmid=11557780 |doi=10.1038/modpathol.3880401 |url=http://www.nature.com/modpathol/journal/v14/n9/full/3880401a.html}}</ref>
*[[Epithelioid sarcoma]].<ref name=pmid10452506>{{cite journal |author=Miettinen M, Fanburg-Smith JC, Virolainen M, Shmookler BM, Fetsch JF |title=Epithelioid sarcoma: an immunohistochemical analysis of 112 classical and variant cases and a discussion of the differential diagnosis |journal=Hum. Pathol. |volume=30 |issue=8 |pages=934–42 |year=1999 |month=August |pmid=10452506 |doi= |url=}}</ref>
 
==Sarcomas cytokeratins==
Most sarcomas are cytokeratin negative.
Most sarcomas are cytokeratin negative.


Latest revision as of 11:49, 30 November 2020

CK20 staining of normal small intestinal mucosa.

Immunohistochemical staining, also immunostaining, is a powerful tool. It is abbreviated IHC.

Utility

Use of immunohistochemistry:[1]

  1. Unknown primary tumours.
  2. Poorly differentiated tumours.
  3. Prognostic markers, e.g. ERBB2 (HER2).
  4. Proving clonality - in the context of hematologic malignancies.
  5. Mutation specific antibodies, eg. IDH-1 R132H.

Method was introduced in 1941 by Coons.[2]

Theory

  • Antigen retrieval.
  • Antibody binds to the antigen.
  • Amplification - needed as the signal is usually too weak.

Signaling systems

  • Avidin-biotin complex.
    • Older.[3]
    • May suffer from endogenous avidin-biotin activity.[4]
      • Higher false positive rates than with polymer based methods.
  • Polymer based methods.
    • Newer.
    • Less prone to false positives.
      • Negative controls not needed or infrequently required.[5]

Signal assessment

  • Manual (Morphology) vs. automated (Speed) counting.
  • Choice of proper chromogen.
    • Dynamic range of DAB is 1-2logs vs. fluorescent probes 2-3logs.
    • Protein expression range can be up to 4 logs in gene amplification (information is missed in IHC).
    • FastRed stains are more suited in melanocytic tumors than DAB.
  • Use of established cutoffs for "intensity" and for "positive" staining.
  • Visual pattern recogniton vs. detecting spatial subtle changes.
  • Detecting differences at low intensity with human eye is less accurate.

Quality control

This is an evolving area in pathology that has been ignored for a surprisingly long time.

It is touched upon the in the quality article in the immunohistochemistry section.

There are at least 62 pre-analytical variables to be considered, that may affect staining results.[6]

Interpretation

To determine whether a stain is (1) done correctly, and (2) positive, one needs to know:

  1. What tissues it stains:
    • Tumour.
    • Normal tissue.
  2. How it stains the various tissues:
    • Patchy.
    • Diffuse.
  3. Where it stains the various tissues:
    • Nucleus.
    • Cytoplasm.
    • Membrane.
    • A combination of the above.

Generally, interpretations can be subjective, and this is especially true when the staining is weak and focal. In other words, "... your weak [positive] stain might be somebody else’s negative."[7]

The cynical might say it is an unwritten rule that: "... if the stain is weak and focal it can be anything you want to make it -- positive or negative -- so it fits perfectly with your diagnosis!"

In cases where the morphology is unclear, it is judicious to have two or more immunostains that support the diagnosis, and negative stains for important entities in the differential diagnosis.

Publications with contradicting results are not uncommon. Differences can arise from the fixation, processing protocol, antibody clone and interpretation.

According to Galloway, one third pathologists substantially overestimate the diagnostic significance of unexpected immunohistochemical staining results.[8]

General (malignant) differential diagnosis

 
 
 
 
 
 
 
 
 
 
Malignancy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epithelial
(Carcinoma)
 
Mesenchymal
(Sarcoma)
 
Germ cell
tumour
 
Neuroendocrine
carcinoma
 
Hematologic
 
Malignant
melanoma
  • Carcinoma.
  • Sarcoma.
    • Vimentin.
      • Many pathologists think this stain is totally useless.
  • Germ cell tumours.
  • Neuroendocrine carcinoma.
    • Chromogranin A.
    • Synaptophysin.
    • CD56.
    • CD57.[10]
  • Melanoma.
    • S-100, HMB-45, Melan A (MART-1).
      • Additional: melanoma cocktail (HMB-45, MART-1)[11], microphthalmia,[12] tyrosinase.[13]
  • Hematologic.
    • Lymphoma/leukemia.
      • CD45 (common leukocyte antigen).
      • CD30.
    • Plasma cell:
      • Kappa.
      • Lambda.
      • CD138.

Keratins

Main article: Keratins

Mark epithelial cells. Are typically seen in carcinomas.

Organ specific

Thyroid and lung

Image: Adenocarcinoma with nuclear TTF-1 positivity (WC).

Breast markers

  • GCDFP-15 (AKA BRST-2) -- specific, but NOT sensitive.
  • ER (estrogen receptor) - in normal breast.
  • PR (progesterone receptor) - in normal breast.
  • HER2/neu - pathological, assoc. with worse prognosis.

Prostate gland

Colorectal carcinoma markers

  • CK20.
  • CDX2.
    • Uncommon in primary lung, breast, pancreas, kidney, gallbladder, liver, urinary bladder, thyroid gland.[20]
  • CEA.

Small bowel

Kidney

Renal cell carcinoma:

  • RCC, EMA, CD10.
  • CK7 -ve in clear cell RCC.
  • AMACR +ve in papillary RCC.
  • D2-40 +ve in ChRCC.

Xanthogranulomatous pyelonephritis:

  • CD68 (for macrophages).

Ovary

  • CA125, CK7+, CK20-.
  • WT1 -- 90% in serous +ve.

Serous markers

Liver

HCC vs. cholangiocarcinoma:

  • TTF-1: ~90-100% +ve (cytoplasmic) in HCC vs. ~10% in cholangiocarcinoma.[23]

Mesothelium

Panel:[24]

  • Mesothelial markers:
  • Carcinoma markers:

Note:

  • One should use two mesothelial markers and two carcinoma markers.[24]

Pancreas

Neuropathology

General:

  • S-100.

Glial:

  • GFAP.

Neuronal:

  • Synaptophysin.
  • Chromogranin.

Glial/Neuronal:

Specific entities:

Tumour (low-grade gliomas):

Miscellaneous

Macrophages

Main article: Histocytoses
  • CD68.

Special:

Special, less common:

One organ versus another

Cervix versus uterus

  • Cervix (typically): CEA +ve,[33] p16 +ve.
    • ... and ER -ve, PR -ve, vimentin -ve.
  • Uterus (typically): vimentin +ve, ER +ve, PR +ve.[34]
    • ... and CEA -ve, p16 -ve.

Liver versus bile duct

Intrahepatic cholangiocarcinoma (ICC) vs. hepatocellular carcinoma (HCC):[35]

  • ICC: CK19 (92.5%), MUC-1 (73.8%) +ve.
  • HCC: HepPar-1 (85.6%), CD34 (87.8%) +ve.

Prostate versus bladder

Prostate adenocarcinoma vs. urothelial carcinoma:

  • Prostate adenocarcinoma: PSA +ve, PSAP +ve, AR +ve, CK7 -ve, CK20 -ve, GATA3 -ve.
  • Urothelial carcinoma: GATA3 +ve, CK7 +ve, CK20 +ve, PSA -ve, PSAP -ve, AR -ve.

Breast versus ovary

Breast carcinoma versus ovarian carcinoma:

Lymphomas

This is covered more extensively in the lymphoma article.

Lymphocytes

  • CD45 (AKA common leukocyte antigen).

B-cells

  • CD20.
  • CD19 (flow only).
  • PAX5.
  • CD79a.

T-cells

  • CD3 - general T-cell marker (marks both CD4 +ve and CD8 +ve cells).
  • CD4.
  • CD8.
  • CD7.
  • CD43.

Specific entities

Follicular lymphoma

  • CD10 +ve, BCL6 +ve.

CLL

Mantle cell lymphoma

Hodgkin's lymphoma

This is covered more extensively in the Hodgkin lymphoma article.

Classic types:

  • CD30 Reed-Sternberg cells (RSCs) +ve ~98%.[39]
  • CD15 Reed-Sternberg cells +ve ~80%, stains neutrophils.

Germ cell tumours

Main article: Germ cell tumours

Seminoma

  • D2-40 +ve.[9]
  • OCT4 +ve.

Embryonal carcinoma

  • CD30 +ve - cytoplasm, cell membrane, Golgi.
    • Rarely positive in seminoma.
  • CK7 +ve.[40]
  • AE1/AE3 +ve.

Yolk sac tumour (endodermal sinus tumour)

  • AFP (alpha fetoprotein).

Choriocarcinoma

  • beta-hCG.

Bare bones mnemonic for GCTs

The germ cell tumour (GCT) IHC mnemonic ABCD:

  • AFP = yolk sac tumour.
  • Beta-hCG = choriocarcinoma.
  • CD30 = embryonal carcinoma.
  • D2-40 = seminoma.

Spindle cell lesions

Main article: Spindle cell lesions

Abbreviated spindle cell panel (memory device SCADS):

  • S100.
  • CD34.
  • AE1/AE3.
  • Desmin.
  • SMA.

A MFH panel:

Muscle markers

  • Desmin - all three types.
  • H-caldesmon - smooth muscle - most specific.
  • Smooth muscle actin (SMA) - smooth muscle.
  • MyoD1 - skeletal muscle.
  • Smooth muscle myosin (abbreviated SMMS).

Proliferation markers

  • MIB1 - an antibody against the protein Ki-67 (a protein expressed in proliferating cells).

Notes:

  • Ki-67 is found in lymphocytes - these are a positive control; lymphocytes should not be confused for (positive) tumour cells.[43]
  • MIB1 should not be confused with mindbomb homolog 1 (MIB-1), a gene that regulates apoptosis.[44]

Carcinomas

CK7 and CK20

CK7+ CK20-

Mnemonic: OBE + lung x2 + H&N x2

CK7- CK20+

CK7+ CK20+

Mnemonic: POOTE.

Note:

CK7- CK20-

Mnemonic: NASH TURP.

Vimentin and cytokeratin positivity

Main article: Vimentin#Vimentin_and_cytokeratin_positivity

A few tumours are positive for both vimentin and cytokeratins.

Sarcomas and cytokeratins

Main article: Keratins

Most sarcomas are cytokeratin negative.

Exceptions - classic:

Others:

See also

References

  1. ↑ Mitchell, Richard; Kumar, Vinay; Fausto, Nelson; Abbas, Abul K.; Aster, Jon (2011). Pocket Companion to Robbins & Cotran Pathologic Basis of Disease (8th ed.). Elsevier Saunders. pp. 175. ISBN 978-1416054542.
  2. ↑ Coons, AH. (Jun 1971). "The development of immunohistochemistry.". Ann N Y Acad Sci 177: 5-9. PMID 4400556.
  3. ↑ Vosse, BA.; Seelentag, W.; Bachmann, A.; Bosman, FT.; Yan, P. (Mar 2007). "Background staining of visualization systems in immunohistochemistry: comparison of the Avidin-Biotin Complex system and the EnVision+ system.". Appl Immunohistochem Mol Morphol 15 (1): 103-7. PMID 17536316.
  4. ↑ Vosse, BA.; Seelentag, W.; Bachmann, A.; Bosman, FT.; Yan, P. (Mar 2007). "Background staining of visualization systems in immunohistochemistry: comparison of the Avidin-Biotin Complex system and the EnVision+ system.". Appl Immunohistochem Mol Morphol 15 (1): 103-7. PMID 17536316.
  5. ↑ Torlakovic, EE.; Francis, G.; Garratt, J.; Gilks, B.; Hyjek, E.; Ibrahim, M.; Miller, R.; Nielsen, S. et al. (Apr 2014). "Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the international ad hoc expert panel.". Appl Immunohistochem Mol Morphol 22 (4): 241-52. doi:10.1097/PAI.0000000000000069. PMID 24714041.
  6. ↑ Engel, KB.; Moore, HM. (May 2011). "Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue.". Arch Pathol Lab Med 135 (5): 537-43. doi:10.1043/2010-0702-RAIR.1. PMID 21526952.
  7. ↑ URL: http://bitesizebio.com/articles/immunohistochemistry-getting-the-stain-you-want/. Accessed on: 1 September 2012.
  8. ↑ Galloway, M. (2011). "Base-rate error in the interpretation of immunohistochemistry.". Patholog Res Int 2011: 636495. doi:10.4061/2011/636495. PMID 21660231.
  9. ↑ 9.0 9.1 Iczkowski KA, Butler SL, Shanks JH, et al (February 2008). "Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors". Hum. Pathol. 39 (2): 275-81. doi:10.1016/j.humpath.2007.07.002. PMID 18045648.
  10. ↑ Kurokawa, M.; Nabeshima, K.; Akiyama, Y.; Maeda, S.; Nishida, T.; Nakayama, F.; Amano, M.; Ogata, K. et al. (May 2003). "CD56: a useful marker for diagnosing Merkel cell carcinoma.". J Dermatol Sci 31 (3): 219-24. PMID 12727026.
  11. ↑ Jani P, Chetty R, Ghazarian DM (April 2008). "An unusual composite pilomatrix carcinoma with intralesional melanocytes: differential diagnosis, immunohistochemical evaluation, and review of the literature". Am J Dermatopathol 30 (2): 174–7. doi:10.1097/DAD.0b013e318165b8fe. PMID 18360125.
  12. ↑ URL: http://www.ncbi.nlm.nih.gov/omim/156845. Accessed on: 18 August 2010.
  13. ↑ Roma, AA.; Magi-Galluzzi, C.; Zhou, M. (Jan 2007). "Differential expression of melanocytic markers in myoid, lipomatous, and vascular components of renal angiomyolipomas.". Arch Pathol Lab Med 131 (1): 122-5. doi:10.1043/1543-2165(2007)131[122:DEOMMI]2.0.CO;2. PMID 17227112.
  14. ↑ Jagirdar J (March 2008). "Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung". Arch. Pathol. Lab. Med. 132 (3): 384–96. PMID 18318581. http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=132&page=384.
  15. ↑ Dralle, H.; Böcker, W. (1982). "[Thyroglobulin immunohistochemistry: new aspects of pathophysiology and differential diagnosis of benign and malignant goitre (author's transl)].". Langenbecks Arch Chir 356 (3): 205-12. PMID 7070163.
  16. ↑ de Micco, C.; Chapel, F.; Dor, AM.; Garcia, S.; Ruf, J.; Carayon, P.; Henry, JF.; Lebreuil, G. (Mar 1993). "Thyroglobulin in medullary thyroid carcinoma: immunohistochemical study with polyclonal and monoclonal antibodies.". Hum Pathol 24 (3): 256-62. PMID 8454270.
  17. ↑ Azumi, N.; Traweek, ST.; Battifora, H. (Aug 1991). "Prostatic acid phosphatase in carcinoid tumors. Immunohistochemical and immunoblot studies.". Am J Surg Pathol 15 (8): 785-90. PMID 1712549.
  18. ↑ http://www.antibodies-online.com/antibody/125649/P504S+alphaMethylacylCoA+Racemace+AMACR+Human/
  19. ↑ Fleischmann, A.; Rocha, C.; Schobinger, S.; Seiler, R.; Wiese, B.; Thalmann, GN. (Apr 2011). "Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases.". Prostate 71 (5): 453-60. doi:10.1002/pros.21259. PMID 20878946.
  20. ↑ Kaimaktchiev, V.; Terracciano, L.; Tornillo, L.; Spichtin, H.; Stoios, D.; Bundi, M.; Korcheva, V.; Mirlacher, M. et al. (Nov 2004). "The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas.". Mod Pathol 17 (11): 1392-9. doi:10.1038/modpathol.3800205. PMID 15205684.
  21. ↑ Anatelli F, Chuang ST, Yang XJ, Wang HL. (2008). "Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy". Am J Clin Pathol. 130 (2): 219-23?. doi:10.1309/WMB5PX57Y4P8QCTY. PMID 18628090.
  22. ↑ The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review. Lamps LW, Folpe AL. Adv Anat Pathol. 2003 Jan;10(1):39-43. Review. PMID 12502967.
  23. ↑ Lei JY, Bourne PA, diSant'Agnese PA, Huang J (April 2006). "Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver". Am. J. Clin. Pathol. 125 (4): 519–25. doi:10.1309/59TN-EFAL-UL5W-J94M. PMID 16627262.
  24. ↑ 24.0 24.1 Marchevsky AM (March 2008). "Application of immunohistochemistry to the diagnosis of malignant mesothelioma". Arch. Pathol. Lab. Med. 132 (3): 397-401. PMID 18318582. http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=132&page=397.
  25. ↑ Goldstein NS, Bassi D (May 2001). "Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold". Am. J. Clin. Pathol. 115 (5): 695–702. doi:10.1309/1NCM-46QX-3B5T-7XHR. PMID 11345833.
  26. ↑ Geller SA, Dhall D, Alsabeh R (March 2008). "Application of immunohistochemistry to liver and gastrointestinal neoplasms: liver, stomach, colon, and pancreas". Arch. Pathol. Lab. Med. 132 (3): 490–9. PMID 18318589.
  27. ↑ Perry, Arie; Brat, Daniel J. (2010). Practical Surgical Neuropathology: A Diagnostic Approach: A Volume in the Pattern Recognition series (1st ed.). Churchill Livingstone. pp. 12. ISBN 978-0443069826.
  28. ↑ Pernick NL, DaSilva M, Gangi MD, Crissman J, Adsay V (November 1999). ""Histiocytic markers" in melanoma". Mod. Pathol. 12 (11): 1072–7. PMID 10574605.
  29. ↑ URL: http://www.ncbi.nlm.nih.gov/omim/605545. Accessed on: 3 February 2011.
  30. ↑ URL: http://www.abcam.com/Macrophage-antibody-MAC387-FITC-ab7429.html. Accessed on: 3 February 2011.
  31. ↑ URL: http://www.abcam.com/Macrophage-antibody-MAC387-ab49408.html. Accessed on: 3 February 2011.
  32. ↑ URL: http://www.ncbi.nlm.nih.gov/omim/604862. Accessed on: 2 February 2011.
  33. ↑ Alkushi A, Irving J, Hsu F, et al. (March 2003). "Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray". Virchows Arch. 442 (3): 271-7. doi:10.1007/s00428-002-0752-4. PMID 12647218.
  34. ↑ URL: http://www.nature.com/modpathol/journal/v19/n8/full/3800620a.html
  35. ↑ [Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma] Dong H, Cong WL, Zhu ZZ, Wang B, Xian ZH, Yu H. Zhonghua Zhong Liu Za Zhi. 2008 Sep;30(9):702-5. Chinese. PMID 19173916.
  36. ↑ Nonaka, D.; Chiriboga, L.; Soslow, RA. (Oct 2008). "Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas.". Am J Surg Pathol 32 (10): 1566-71. doi:10.1097/PAS.0b013e31816d71ad. PMID 18724243.
  37. ↑ Kanner, WA.; Galgano, MT.; Stoler, MH.; Mills, SE.; Atkins, KA. (Oct 2008). "Distinguishing breast carcinoma from Müllerian serous carcinoma with mammaglobin and mesothelin.". Int J Gynecol Pathol 27 (4): 491-5. doi:10.1097/PGP.0b013e31817d5340. PMID 18753974.
  38. ↑ URL: http://atlasgeneticsoncology.org/Genes/BCL1.html. Accessed on: 17 December 2010.
  39. ↑ Humphrey, Peter A; Dehner, Louis P; Pfeifer, John D (2008). The Washington Manual of Surgical Pathology (1st ed.). Lippincott Williams & Wilkins. pp. 567. ISBN 978-0781765275.
  40. ↑ Cheville JC, Rao S, Iczkowski KA, Lohse CM, Pankratz VS (April 2000). "Cytokeratin expression in seminoma of the human testis". Am. J. Clin. Pathol. 113 (4): 583–8. doi:10.1309/3QLC-5MF1-JYXU-A5XX. PMID 10761461.
  41. ↑ Tadrous, Paul.J. Diagnostic Criteria Handbook in Histopathology: A Surgical Pathology Vade Mecum (1st ed.). Wiley. pp. 107. ISBN 978-0470519035.
  42. ↑ URL: http://ajp.amjpathol.org/cgi/content/full/160/3/759. Accessed on: 3 August 2010.
  43. ↑ Hadzi-Mihailovic, M.; Cakic, S.; Jankovic, S.; Raybaud, H.; Nedeljkovic, N.; Jankovic, L.. "Ki-67 expression in oral lichen planus.". J BUON 17 (1): 132-7. PMID 22517707.
  44. ↑ http://www.genenames.org/data/hgnc_data.php?hgnc_id=21086
  45. ↑ Tazi, EM.; Lalya, I.; Tazi, MF.; Ahellal, Y.; M'rabti, H.; Errihani, H. (2010). "Transitional cell carcinoma of the ovary: a rare case and review of literature.". World J Surg Oncol 8: 98. doi:10.1186/1477-7819-8-98. PMID 21073751.

External links

Retrieved from "https://librepathology.org/w/index.php?title=Immunohistochemical_staining&oldid=51031"